Semaglutide and your kidneys: the warning and the outcome data are two different things

Before you read. This page explains what two FDA labels say. It is educational, it cannot assess your kidney function, and nothing on it is a reason to start, stop or switch a medicine. One thing here is time-sensitive: if you are vomiting persistently, have ongoing diarrhoea, cannot keep fluids down, or are passing much less urine than usual, contact your care team promptly — that is the situation the label's kidney warning describes, and it is treatable when it is caught early.

Quick answer

Two opposite questions get typed into a search box in almost the same words, and both have yes-shaped answers.

Can it harm the kidneys? The semaglutide tablet label carries a warning — acute kidney injury due to volume depletion, based on postmarketing reports, some requiring haemodialysis. Read the heading rather than the first three words: due to volume depletion. The route runs through dehydration from gastrointestinal reactions, not through a direct effect on the kidney.

Can it protect the kidneys? The Ozempic injection label carries an indication to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That came from FLOW, a trial of 3,533 patients followed for a median of 41 months.

Rybelsus and Ozempic tablets do not carry that indication. Same molecule, different product, and the difference is what was studied rather than what is believed.

One more fact that surprises people: the label recommends no dose change for renal impairment, including in kidney failure.

Keep a symptom log with dates on it →

The warning, in full

Section 5.5 of the tablet label is four sentences, and the mechanism is stated rather than implied:

There have been postmarketing reports of acute kidney injury in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to RYBELSUS or OZEMPIC tablets that could lead to volume depletion, especially during dosage initiation and escalation.

Three details worth extracting.

Postmarketing. These were reported after approval rather than counted in a controlled trial. The label's own caveat elsewhere applies: the reporting population is of uncertain size, so a frequency cannot be reliably estimated and causation cannot be established.

The heading names the cause. Not "acute kidney injury" but "acute kidney injury due to volume depletion." A label heading is a considered piece of drafting, and this one is telling you which chain of events it is describing.

The monitoring instruction has a window. Especially during dosage initiation and escalation — which is also when the label says gastrointestinal reactions cluster. The two warnings point at the same weeks. Symptom by symptom against the label goes through the reactions themselves.

What actually triggers it

The picture the label is drawing is ordinary and preventable, which is the useful part.

Someone increases their dose. Nausea and vomiting follow, as the label says they commonly do around escalation. Appetite falls, so meals shrink — and with them the fluid that normally arrives at mealtimes. Perhaps there is diarrhoea too. Over several days, fluid out exceeds fluid in, blood volume drops, and the kidneys, which depend on adequate perfusion, get less blood than they need.

That is volume depletion, and it is not a mysterious drug toxicity. It is what happens to anyone who loses more fluid than they take in — the drug's contribution is that it makes the losing more likely and the replacing less appealing.

It is also why the constipation route matters more than it sounds. Fibre without fluid, or an osmotic laxative on a low intake, pulls in the same direction as vomiting does, and the dehydration trap in treating constipation covers that specific version.

The practical rule. Sustained vomiting or diarrhoea, particularly during a dose increase, is the situation this warning is about — and it is a reason to contact your care team rather than to wait it out. Passing much less urine than usual, or urine that is unusually dark, belongs in the same call. Why escalation weeks are when most of this happens covers the timing.

The other direction: what FLOW showed

Now the half of the picture that "does it damage kidneys" searches never surface, because it is on a different label.

FLOW was a randomised, double-blind, placebo-controlled, event-driven trial in adults with type 2 diabetes and chronic kidney disease. The entry criteria were specific: an eGFR of 25 to 75 mL/min/1.73m², with a urine albumin-to-creatinine ratio above 100 and below 5,000 mg/g, and standard-of-care background therapy including a maximum tolerated dose of a RAAS-blocking agent unless contraindicated.

3,533 patients were randomised to Ozempic 1 mg once weekly or placebo and followed for a median of 41 months. Mean age 67. Mean baseline eGFR 47, with 11% already below 30. Median baseline urine albumin-to-creatinine ratio 568 mg/g. At baseline, 95% were on an ACE inhibitor or ARB, 16% on an SGLT2 inhibitor, 76% on a statin.

The primary endpoint was a composite: a sustained decline in eGFR of 50% or more, sustained eGFR below 15, chronic renal replacement therapy, and cardiovascular or kidney death. Semaglutide was superior to placebo in reducing it, and that result is why the indication now appears on the Ozempic injection label.

Read the population before reading the result. This was a trial in people who already had significant kidney disease and albuminuria, already on maximal RAAS blockade. It is not a study of kidney protection in people with normal kidney function, and it did not use a tablet.

The weeks this warning is about are dose-change weeks, and those are dates. Takely keeps your dose changes and daily symptom notes on one private timeline, so "vomiting for three days after the increase" is a record rather than a recollection. Open Takely in your browser →

Why the tablet does not carry the same indication

The honest answer is regulatory rather than pharmacological, and it is worth being precise about.

A label carries an indication when a trial has demonstrated the effect for that product at that dose in that population. FLOW studied Ozempic 1 mg by weekly injection. That is what the resulting indication describes. The oral tablets were not in the trial, so nothing follows from it about them — not a positive claim, and not a negative one.

There is a related trap here that is worth naming, because this site does not go in for it. Reasoning across trials — taking a result from a weekly injection at one dose in one population and treating it as though it applied to a daily tablet in another — is the kind of argument that looks quantitative and supports no conclusion. It is not evidence about the tablet. Only a trial of the tablet would be.

What can be said is what the labels say. What changes between a tablet and an injection covers the practical differences, and the conversions the labels actually give covers what is printed about moving between them.

Dosing when kidney function is already reduced

Section 8.6 of the tablet label is short and, for most people, reassuring:

The recommended dosage of RYBELSUS and OZEMPIC tablets in patients with renal impairment is the same as those with normal renal function.

Two supporting facts sit behind it. Safety and effectiveness were evaluated in a 26-week clinical study that included 324 patients with moderate renal impairment — eGFR 30 to 59. And in patients with renal impairment including end-stage renal disease, no clinically relevant change in semaglutide pharmacokinetics was observed.

The pharmacology explains the second one. Semaglutide is cleared primarily by metabolism — proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain — rather than by the kidney. Only about 3% of the absorbed dose is excreted in the urine as intact semaglutide. A drug that the kidneys barely handle is not one whose levels swing when kidney function changes.

None of which makes reduced kidney function irrelevant to your prescriber. It means the dose is not the lever they would reach for.

Reading a kidney result

Two numbers appear throughout this page and are worth knowing, because they are the ones your results letter will use.

eGFR — estimated glomerular filtration rate, in mL/min/1.73m². Roughly, how much blood the kidneys are filtering, adjusted for body size. Higher is better. The FLOW entry range of 25 to 75 describes moderate to severe reduction; the tablet trial's 30 to 59 band is what the label calls moderate impairment.

UACR — urine albumin-to-creatinine ratio, in mg/g. How much albumin is leaking into the urine, which is often the earlier signal. Above 300 is generally described as severely increased; FLOW's median entry value was 568, with 69% of participants above 300.

A single reading of either can be moved by dehydration, which is one more reason the warning at the top of this page and the numbers at the bottom of it are connected. If a result arrives during a week of vomiting, that context belongs with it.

What is worth watching

Three things, and none of them requires equipment.

Fluid, roughly. Not to the millilitre — enough to notice the week it collapsed. That week is the one the label is describing.

Any stretch of vomiting or diarrhoea, with dates. Duration is what turns a symptom into the situation in section 5.5, and duration is exactly what gets rounded off in memory.

Urine output and colour, when you are unwell. A sharp drop, or persistently dark urine, alongside gastrointestinal symptoms is a call rather than an observation.

A symptom log with dates on it is what makes the first two available at the appointment. The blood tests are your prescriber's to order; the timeline is yours to keep.

Frequently asked questions

Does Rybelsus damage your kidneys?

The label carries a warning about acute kidney injury due to volume depletion, based on reports received after approval, and states that the majority of reported events occurred in patients who had gastrointestinal reactions leading to dehydration. The described route runs through fluid loss rather than through a direct effect on the kidney, which is why the monitoring instruction is tied to dose initiation and escalation.

Does semaglutide protect the kidneys?

The Ozempic injection label carries an indication to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial. The oral tablets do not carry that indication, and no conclusion about them follows from a trial they were not in.

Can I take Rybelsus with chronic kidney disease?

The label states that the recommended dosage in patients with renal impairment is the same as for normal renal function, and reports no clinically relevant pharmacokinetic change including in end-stage renal disease. Whether the medicine is right for you is still a prescriber's judgement, which the dosing statement does not answer.

Do I need a dose adjustment for reduced kidney function?

Not according to the label. Semaglutide is cleared mainly by metabolism rather than by the kidney — only about 3% of the absorbed dose is excreted in urine as intact drug — which is the reason the recommended dosage does not change.

What are the warning signs of kidney trouble on this medicine?

The label points at the trigger rather than the symptoms: gastrointestinal reactions leading to dehydration, particularly during a dose increase. Passing much less urine than usual, being unable to keep fluids down, or persistent vomiting or diarrhoea are reasons to contact your care team rather than to wait.

Is dehydration from vomiting genuinely enough to injure a kidney?

It is the mechanism the label names. Kidneys depend on adequate blood flow, and sustained fluid loss reduces it. This is why the label's instruction is to monitor renal function in patients reporting reactions that could lead to volume depletion, rather than to monitor everyone routinely.

Primary sources and further reading

Labels are revised without notice and indications are added over time. Everything above was read off those documents on 8 September 2026.